EMAIL THIS PAGE TO A FRIEND

Breast Cancer Research and Treatment

A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.


PMID 25528022

Abstract

We're sorry this abstract is currently not available.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

D5011
5′-Deoxy-5′-(methylthio)adenosine
C11H15N5O3S